Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/02/2003US20030186986 Agent for improving learning or memory
10/02/2003US20030186985 Oxyiminoalkanoic acid derivatives
10/02/2003US20030186984 Substituted cyclohexane derivatives
10/02/2003US20030186983 C-5 Modified indazolylpyrrolotriazines
10/02/2003US20030186981 Antiinflammatory agents; osteoporosis; rheumatic diseases; autoimmune diseases
10/02/2003US20030186980 Skin disorders; parasiticides
10/02/2003US20030186978 Novel telomerase inhibitors
10/02/2003US20030186977 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
10/02/2003US20030186976 Benzofurylpyrone derivatives
10/02/2003US20030186975 Coumarin derivatives with comt inhibiting activity
10/02/2003US20030186974 Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
10/02/2003US20030186971 Using 1,3-benothiazine compound
10/02/2003US20030186970 Androgen receptor modulator compounds and methods
10/02/2003US20030186969 Benzodiazepine derivatives
10/02/2003US20030186968 Psychological disorders; central nervous system disorders
10/02/2003US20030186967 Anticancer agents; antiinflammatory agents; bone disorders; viricides
10/02/2003US20030186966 Antiinflammatory agents; autoimmune disease; antiallergens
10/02/2003US20030186964 Piperdines for use as orexin receptor antagonists
10/02/2003US20030186963 Central nervous system disorders; cardiovascular disorders
10/02/2003US20030186961 Central nervous system disorders; vision defects
10/02/2003US20030186960 Nervous system regeneration
10/02/2003US20030186959 Central nervous system disorders
10/02/2003US20030186958 Viricides, vision defects, oral diseases, antiarthritic agents, multiple sclerosis, anticancer agents
10/02/2003US20030186957 Methods of treatment and formulations of cephalosporin
10/02/2003US20030186956 Using inert gas; controlling humidity
10/02/2003US20030186954 Administering estriol
10/02/2003US20030186953 Alzheimer's, Parkinson's disease, brain disorders
10/02/2003US20030186952 Anticholesterol agents; cardiovascular disorders
10/02/2003US20030186951 Compositions and methods for enhancing corticosteroid delivery
10/02/2003US20030186950 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
10/02/2003US20030186949 Modulate immunology response; anticancer agents
10/02/2003US20030186948 O-linked N-acetylglucosamine pathway in the pathogenesis of neurodegeneration and diabetes
10/02/2003US20030186946 Suppression of cytotoxic protein conformers
10/02/2003US20030186945 Method of preparing and use of prodrugs of betulinic acid derivatives
10/02/2003US20030186943 Substituted gamma-phenyl-delta-lactams and uses related thereto
10/02/2003US20030186942 Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
10/02/2003US20030186941 Cyclopenteneone derivatives
10/02/2003US20030186940 Method for preparing a polydispersed saccharide composition and resulting polydispersed saccharide composition
10/02/2003US20030186938 Tablets for immediate oral administration; improved taste; antidepressants; for treatment of obsessive compulsive disorder and panic
10/02/2003US20030186937 Produced from fermenting suspension of non-pathogenic saprophytic filamentous fungus; for use in food products to improve structure, texture, and stability; for prevention or treatment of immune disorders, tumors or microbial infections
10/02/2003US20030186936 Gene therapy; lyases; hyaluronidase; anticancer agents (retinoblastomas); kits
10/02/2003US20030186934 For use as skin-whitening agents; side effects reduction
10/02/2003US20030186933 Preparation of aqueous clear solution dosage forms with bile acids
10/02/2003US20030186932 Polysaccharides comprising galactose, arabinose, and glucuronic acid units; for treatment of arthritis/inflammation
10/02/2003US20030186931 Comprises trehalose; for treatment of Gougerot-Sjogren Syndrome
10/02/2003US20030186928 Method for reducing intraocular pressure
10/02/2003US20030186927 Such as uridine 5'-diphosphoric acid for corneal epithelial migration promotion
10/02/2003US20030186926 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
10/02/2003US20030186925 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
10/02/2003US20030186922 Therapeutic use of cis-element decoys in vivo
10/02/2003US20030186917 Method of treating edematous retinal disorders
10/02/2003US20030186912 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
10/02/2003US20030186906 Mixture comprising an inhibitor or suppresor of a gene and a molecule binding to an expression product of that gene
10/02/2003US20030186902 Use of a pituitary tumor transforming gene peptide which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner
10/02/2003US20030186901 Method of inhibiting neurotrophin-receptor binding
10/02/2003US20030186900 Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus
10/02/2003US20030186899 Produced by culturing Saccharopolyspora species LW107129 (NRRL 30141); insecticidal and acaricidal activity; useful intermediates for preparing spinosyn analogs
10/02/2003US20030186896 Crystalline form of perindopril tert-butylamine salt
10/02/2003US20030186894 Dry powder compositions having improved dispersivity
10/02/2003US20030186890 Amphipathic linear peptides and formulations containing said peptides
10/02/2003US20030186882 Methods and compositions for treating and preventing distal bowel lesions
10/02/2003US20030186880 Combination therapy using trefoil peptides
10/02/2003US20030186872 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
10/02/2003US20030186845 Compositions for preventing urinary calculus
10/02/2003US20030186843 Powder comprising active material and further comprising an indicator material that is capable of indicating to a patient that a dose of the active material has been administered
10/02/2003US20030186842 Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family
10/02/2003US20030186838 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
10/02/2003US20030186421 Comprises lipoprotein associated phospholipase A2 (Lp-PLA2) for diagnosing and treating atherosclerosis; enzyme inhibitors
10/02/2003US20030186419 Masp-3, a complement-fixing enzyme, and uses for it
10/02/2003US20030186401 Method of recovering pinitol or chiro-inositol in high yield from soy fractions
10/02/2003US20030186370 Comprises nucleotide sequences coding nicotinic-acetylcholine receptor (5-ht3) for use in screening nematocides, insecticides and/or pesticides
10/02/2003US20030186337 Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
10/02/2003US20030186290 Gene involved in CADASIL, method of diagnosis and therapeutic application
10/02/2003US20030186271 Pharmaceutical compositions in particulate form
10/02/2003US20030186269 Ssa-56 kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
10/02/2003US20030186244 Using stored nucleotide sequence information to screen genome databases to detect restriction fragment length polymorphisms which are associated with genetic disorders
10/02/2003US20030186191 Dispensing apparatus and cartridge
10/02/2003US20030185921 Optionally esterified 5-ethylidene-4-carboxy-2-pyranones as a cytoprotective agent
10/02/2003US20030185917 Synergistic pharmaceutical composition for diabetic nephropathy
10/02/2003US20030185915 Zinc Pyrithione; corticosteroid, especially triamcinolone acetonide; Polysorbate 80; fungicide or bactericide; carrier
10/02/2003US20030185914 Process for isolating artemisinin from artemisia annua
10/02/2003US20030185912 Anti-microbial compositions and methods of using same
10/02/2003US20030185910 Cancer preventive composition comprising ginsenoside glycosides of red ginseng
10/02/2003US20030185908 Monoamine oxidase (MAO) inhibitors and uses thereof
10/02/2003US20030185907 Method for treatment of inflammation and pain in mammals
10/02/2003US20030185906 Composition useful as hepatoprotectants comprising extract of plant Cryptolepis Buchanani and a method thereof
10/02/2003US20030185905 Plant extracts for the treatment of increased bone resorption
10/02/2003US20030185904 Selenium-compound (e.g., sodium selenite or selenate or selenomethionine); chondroitin sulfate; glucosamine; and methylsulfonylmethane.
10/02/2003US20030185902 Concentrate includes a complex resulting from an in-situ reaction of a cation source, an oxidant, a halide source having at least one iodine atom, and a non-mineral acid
10/02/2003US20030185901 Methods of treating conditions with a metal-containing material
10/02/2003US20030185900 Sodium metasilicate, borax, sodium thiosulfate, potassium carbonate, refined sugar (C12H22O11), and water.
10/02/2003US20030185895 Spherical polymer particle (e.g., a polyvinyl acetal) having an internal reservoir region including large pores containing therapeutic agent and a metering region having fewer relatively large pores.
10/02/2003US20030185894 Process for producing nanoparticles of paclitaxel and albumin
10/02/2003US20030185893 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
10/02/2003US20030185891 Glycogen phosphorylase inhibitor
10/02/2003US20030185890 Compositions and methods for polynucleotide delivery
10/02/2003US20030185888 Volume efficient controlled release dosage form
10/02/2003US20030185887 Controlled release oral dosage form of beta-adrenergic blocking agents
10/02/2003US20030185885 Non-granulated levothyroxine pharmaceutical compositions
10/02/2003US20030185884 Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
1 ... 5323 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 ... 7860